• September 13, 2021
  • No Comment

Sinovac launches clinical trial of COVID-19 vaccine on children, teenagers

Sinovac launches clinical trial of COVID-19 vaccine on children, teenagers

 Chinese pharmaceutical company Sinovac Biotech on Friday launched the Phase III clinical trial of its COVID-19 vaccine on a group of children and teenagers between six months and 17 years old in South Africa.

The study, carried out in collaboration with South African company Numolux Group, has enrolled approximately 2,000 participants in the country, who will receive two doses of Sinovac’s CoronaVac vaccine or a placebo, 28 days apart. The efficacy assessment will be based on relevant indicators.

Numolux CEO Hilton Klein said that there are roughly 24 million children and teenagers in South Africa and that if the vaccine made by Sinovac is approved for use on them, it will help the country reach herd immunity more quickly.

The South African Health Products Regulatory Authority authorized the use of the CoronaVac vaccine on the country’s adults in July.

Views: 13

Related post

Breaking news! Museveni Announces Full Reopening Of The Economy, Bars To Reopen In Two Weeks

Breaking news! Museveni Announces Full Reopening Of The Economy,…

President Museveni has directed that bars, music concerts, stadiums and cinemas will be allowed to operate again in January as the…
Omicron Variant: Scientists ask Museveni to delay full reopening of the economy

Omicron Variant: Scientists ask Museveni to delay full reopening…

Scientists under the National Covid-19 task force have asked President Museveni to extend the full reopening of the economy for another…
Police arrest more members of new rebel group allegedly planning to overthrow Museveni’s government

Police arrest more members of new rebel group allegedly…

Police have arrested 21 more people over their involvement in the activities of a newly formed rebel group that targets police…
0 0 votes
Article Rating
ugbettips

Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments